CurrentAnthemPolicy 04-302

Local Delivery of Chemotherapeutic Agents/Antimicrobial Agents

Defines clinical appropriateness and coverage guidance for use of locally delivered chemotherapeutic/antimicrobial agents (LDCA/LDAA) as adjunctive therapy in periodontal disease management for dental providers and billing staff.

Policy Summary

PayerAnthem

PolicyLocal Delivery of Chemotherapeutic Agents/Antimicrobial Agents

Policy CodePolicy 04-302

Change TypeRevised

Effective Date

Next Review Date

Key ActionProvide a current (within 12 months), dated 6-point periodontal charting and document periodontal diagnosis including staging and grading per AAP/ADA, including pocket depth, bleeding/suppuration and history of attachment loss.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>= 5minimum periodontal probing depth for eligible sites

6 wks–6 mostime window post scaling/root planing or surgery when LDCA/LDAA may be performed

within 12 morequired dated post-treatment 6-point periodontal charting

1policy guideline number (internal)

When Local Delivery of Antimicrobials Is Medically Necessary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Appropriateness / Medically Necessary Criteria

Local delivery of chemotherapeutic/antimicrobial agents is appropriate as adjunctive therapy when ALL of the following are met:

ALL of the following

Definitive non-surgical and/or surgical periodontal treatment (including scaling and root planing) has been completed for the site.
Adequate time for healing has been allowed: between 6 weeks and 6 months after scaling and root planing or periodontal surgery.6 weeks to 6 months
Site demonstrates refractory/active disease defined as a periodontal pocket measuring 5 millimeters or greater.>= 5 mm
Site shows persistent signs of inflammation such as spontaneous bleeding, bleeding on probing, suppuration, and/or a history of increasing pocket depth with associated clinical attachment loss.
A current (within 12 months), dated, post-periodontal maintenance and/or post-periodontal surgery 6-point periodontal charting is available.within 12 months
Only natural teeth with favorable periodontal outcomes will be considered for benefit.
Periodontal diagnosis including staging and grading per AAP/ADA is documented.

Adjunctive use during periodontal maintenance

LDCA/LDAA may be indicated during maintenance when ALL of the following are met:

ALL of the following

Localized recurrent and/or residual sites with inflammation are present at periodontal maintenance appointments.
Sites meet the refractory criteria (pocket >= 5 mm with bleeding/suppuration/etc.).>= 5 mm

Contraindications / Not appropriate

Use is considered not appropriate when any of the following apply:

ANY of the following

Periodontal probing depths are less than 5 millimeters.
Generalized periodontitis is present requiring more comprehensive intervention; surgical therapies should be considered instead of localized delivery.
Use of LDCA/LDAA for regeneration of alveolar bone — considered experimental and investigational.

Additional review considerations

Special review conditions:

ANY of the following

Multiple sites of recurrent/residual inflammation after scaling and root planing may require more extensive periodontal therapeutics (e.g., surgical procedures) rather than repeat LDCA/LDAA.
Use in medically compromised patients will be reviewed on a case-by-case basis and requires physician documentation.

Relevant CDT Codes

Relevant CDT codes (informational)CDT

D4381	Localized delivery of antimicrobial agents via a controlled release vehicle into diseased crevicular tissue per tooth
D4341	Periodontal scaling and root planing, four or more teeth per quadrant
D4342	Periodontal scaling and root planing, one to three teeth per quadrant
D4346	Scaling in the presence of generalized moderate or severe gingival inflammation full mouth, after oral exam
D4910	Periodontal maintenance
D4999	Unspecified periodontal procedure, by report
D6081	Scaling and debridement in the presence of inflammation or mucositis of a single implant, including cleaning of the implant surfaces, without flap entry and closure.

Documentation, Prior Authorization, and Denial Risks

Documentation Required

Record post-treatment charting and diagnosis

Provide a current (within 12 months), dated 6‑point periodontal charting and document a periodontal diagnosis including staging and grading per AAP/ADA; include evidence of pocket depth, bleeding/suppuration and history of attachment loss.

D4381
D4910
D4341
D4342

Prior Authorization

Case-by-case review for medically compromised patients

Use in medically compromised patients will be reviewed on a case‑by‑case basis and requires physician documentation to support appropriateness.

Denial Risk

Denial risk for non-qualifying sites or indications

Services for periodontal sites with probing depths less than 5 mm, generalized periodontitis requiring more comprehensive/surgical therapy, or use of LDCA/LDAA for alveolar bone regeneration are considered not appropriate and may be denied.

Primary affected code: D4381

Clinical Background

Scaling and root planing is the standard non-surgical therapy for chronic periodontitis and is highly effective; in most cases diseased sites will respond and will not require adjunctive local antimicrobials. Local delivery of sustained-release antimicrobial or chemotherapeutic agents (LDCA/LDAA) can be used as an adjunct for isolated refractory pockets that do not respond to initial therapy following definitive non-surgical and/or surgical periodontal treatment. Refractory disease sites are defined as periodontal pockets measuring ≥ 5 millimeters with persistent signs of inflammation such as spontaneous bleeding or bleeding on probing, suppuration, and/or increasing clinical attachment loss. The evidence and plan do not support the use of LDCA/LDAA for the regeneration of alveolar bone; this application is considered experimental and investigational.